Search

To exploit the B-lymphocyte antigen-CD20 binding capa­city of the Ibritumomab tiuxetan (IBTN) monoclonal antibody (mAb) for imaging, the over-expression of B cells in non-Hodgkin's lymphoma (NHL) (a myeloproliferative disorder of the lymphatic system) was investigated. In the current investigation, we present the labeling of the IBTN with technetium-99m (99mTc) through [99mTc(CO)3]+ precursor for radioimmunoimaging (RII) of the tumor prior to its treatment with 90Y labeled IBTN. Labeled IBTN was radiobiologically characterized in terms of radiochemical purity, in vitro stability in human plasma, immunoreactivity, binding with Raji and Ramos cells and biodistribution in a female nude mouse (FNM) model. It was observed that the reduced IBTN (rIBTN) showed more promising radiobiologic characteristics than the nonreduced IBTN. Significantly higher transchelation was seen in excess cysteine compared with histidine. The radioconjugate showed higher saturated binding affinity with CD20 antigen. Significantly higher target (tumor) to background ratios were observed 1 h post-injection (p.i.). Based on radiochemical purity, in vitro stability, immunoreactivity, binding and biodistrubtion in the FNM model, we recommend the radiolabeling of the rIBTN using tricarbonyl technique as a potential RII agent. [ABSTRACT FROM AUTHOR]

OBJECTIVES: B-cell Non-Hodgkin's lymphoma (B-NHL) is one of the increasing cancer species over the world. DICER1 gene is a member of ribonuclease type III family and it plays a crucial role in biogenesis of miRNAs that regulates the gene expression in posttranscriptional level. In addition, studies have showed that the germline mutations in DICER1 exon 11 may be hazardous because they result in frame shift and exon 25 mutations play role in biogenesis of miRNA. BAFF is expressed by immune system cells such as monocytes, macrophages, dendritic cells, a subtype of T-lymphocytes and B-lymphocytes. Studies, that has been done till now, show high levels BAFF gene expression in malignant B-cells of patients with B-NHL. MATERIAL&METHODS: In our study, DICER1 c.+3473A>G (rs3742330) and BAFF c.-871C>T (rs9514828) single nucleotide polymorphisms in DNA materials, that were isolated from peripheral blood samples of 60 patients that were diagnosed B-cell non-Hodgkin's lymphoma and 30 healthy people matched with patients by age, sex and ethnicity, were examined with PCR-RFLP method. RESULTS: The detection of mutation existence in exon11 and 25 in DICER1 gene was examined by SANGER sequencing analysis. Chi-Square and Fisher tests were used for evaluation of the results between control and patient groups. No significant results were found between the two groups (p > 0, 05). CONCLUSIONS: In our study, the presence of mutations and polymorphisms related to DICER1 and BAFF genes was not found in patients with B cell non- Hodgkin lymphoma. It is thought that the disease may be related to other factors in the patient group in our study. [ABSTRACT FROM AUTHOR]